These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25395427)

  • 1. Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412.
    Hussain K; Hargreaves CE; Roghanian A; Oldham RJ; Chan HT; Mockridge CI; Chowdhury F; Frendéus B; Harper KS; Strefford JC; Cragg MS; Glennie MJ; Williams AP; French RR
    Blood; 2015 Jan; 125(1):102-10. PubMed ID: 25395427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.
    Römer PS; Berr S; Avota E; Na SY; Battaglia M; ten Berge I; Einsele H; Hünig T
    Blood; 2011 Dec; 118(26):6772-82. PubMed ID: 21931118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Fcγ receptors compete for TGN1412 binding that determines the antibody's effector function.
    Dudek S; Weißmüller S; Anzaghe M; Miller L; Sterr S; Hoffmann K; Hengel H; Waibler Z
    Eur J Immunol; 2019 Jul; 49(7):1117-1126. PubMed ID: 31002172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.
    Thaventhiran T; Alhumeed N; Yeang HX; Sethu S; Downey JS; Alghanem AF; Olayanju A; Smith EL; Cross MJ; Webb SD; Williams DP; Bristow A; Ball C; Stebbings R; Sathish JG
    MAbs; 2014; 6(5):1290-9. PubMed ID: 25517314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell contact-dependent priming and Fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response.
    Bartholomaeus P; Semmler LY; Bukur T; Boisguerin V; Römer PS; Tabares P; Chuvpilo S; Tyrsin DY; Matskevich A; Hengel H; Castle J; Hünig T; Kalinke U
    J Immunol; 2014 Mar; 192(5):2091-8. PubMed ID: 24470499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.
    Eastwood D; Findlay L; Poole S; Bird C; Wadhwa M; Moore M; Burns C; Thorpe R; Stebbings R
    Br J Pharmacol; 2010 Oct; 161(3):512-26. PubMed ID: 20880392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy?
    Sandilands GP; Wilson M; Huser C; Jolly L; Sands WA; McSharry C
    Clin Exp Immunol; 2010 Dec; 162(3):516-27. PubMed ID: 20964641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.
    Stebbings R; Findlay L; Edwards C; Eastwood D; Bird C; North D; Mistry Y; Dilger P; Liefooghe E; Cludts I; Fox B; Tarrant G; Robinson J; Meager T; Dolman C; Thorpe SJ; Bristow A; Wadhwa M; Thorpe R; Poole S
    J Immunol; 2007 Sep; 179(5):3325-31. PubMed ID: 17709549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture.
    Findlay L; Sharp G; Fox B; Ball C; Robinson CJ; Bird C; Stebbings R; Eastwood D; Wadhwa M; Poole S; Thorpe R; Thorpe SJ
    Cytokine; 2011 Jul; 55(1):141-51. PubMed ID: 21493088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08.
    Tabares P; Berr S; Römer PS; Chuvpilo S; Matskevich AA; Tyrsin D; Fedotov Y; Einsele H; Tony HP; Hünig T
    Eur J Immunol; 2014 Apr; 44(4):1225-36. PubMed ID: 24374661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody C region influences TGN1412-like functional activity in vitro.
    Ball C; Fox B; Hufton S; Sharp G; Poole S; Stebbings R; Eastwood D; Findlay L; Parren PW; Thorpe R; Bristow A; Thorpe SJ
    J Immunol; 2012 Dec; 189(12):5831-40. PubMed ID: 23150712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation.
    Weissmüller S; Semmler LY; Kalinke U; Christians S; Müller-Berghaus J; Waibler Z
    Blood; 2012 Jun; 119(26):6268-77. PubMed ID: 22577174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.
    Vessillier S; Eastwood D; Fox B; Sathish J; Sethu S; Dougall T; Thorpe SJ; Thorpe R; Stebbings R
    J Immunol Methods; 2015 Sep; 424():43-52. PubMed ID: 25960173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activity.
    Chenoweth AM; Esparon S; Wines BD; Schuurman J; Labrijn AF; Hogarth PM
    Immunol Cell Biol; 2023 Aug; 101(7):657-662. PubMed ID: 36997299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models.
    Yan H; Bhagwat B; Sanden D; Willingham A; Tan A; Knapton AD; Weaver JL; Howard KE
    Toxicol Appl Pharmacol; 2019 Jun; 372():57-69. PubMed ID: 30914376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties.
    Elsayed A; Pellegrino C; Plüss L; Peissert F; Benz R; Ulrich F; Thorhallsdottir G; Plaza SD; Villa A; Mock J; Puca E; De Luca R; Manz MG; Halin C; Neri D
    MAbs; 2023; 15(1):2220839. PubMed ID: 37288872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. After TGN1412: recent developments in cytokine release assays.
    Stebbings R; Eastwood D; Poole S; Thorpe R
    J Immunotoxicol; 2013; 10(1):75-82. PubMed ID: 22967038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412.
    Findlay L; Eastwood D; Stebbings R; Sharp G; Mistry Y; Ball C; Hood J; Thorpe R; Poole S
    J Immunol Methods; 2010 Jan; 352(1-2):1-12. PubMed ID: 19895813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account.
    Hünig T
    FEBS J; 2016 Sep; 283(18):3325-34. PubMed ID: 27191544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor.
    Chu SY; Yeter K; Kotha R; Pong E; Miranda Y; Phung S; Chen H; Lee SH; Leung I; Bonzon C; Desjarlais JR; Stohl W; Szymkowski DE
    Arthritis Rheumatol; 2014 May; 66(5):1153-64. PubMed ID: 24782179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.